Cost effectiveness of Daclatasvir/Asunaprevir versus Peginterferon/Ribavirin and protease inhibitors for the treatment of Hepatitis C Genotype 1B in Chile
May 1, 2015, 00:00
10.1016/j.jval.2015.03.1309
https://www.valueinhealthjournal.com/article/S1098-3015(15)01366-2/fulltext
Title :
Cost effectiveness of Daclatasvir/Asunaprevir versus Peginterferon/Ribavirin and protease inhibitors for the treatment of Hepatitis C Genotype 1B in Chile
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)01366-2&doi=10.1016/j.jval.2015.03.1309
First page :
A225
Section Title :
Gastrointestinal Disorders
Open access? :
No
Section Order :
771